NexturnBioscience Co. Ltd
Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology. The company was formerly known as KMT Incorporated and chan… Read more
NexturnBioscience Co. Ltd (089140) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.019x
Based on the latest financial reports, NexturnBioscience Co. Ltd (089140) has a cash flow conversion efficiency ratio of 0.019x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.51 Billion) by net assets (₩240.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NexturnBioscience Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how NexturnBioscience Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NexturnBioscience Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NexturnBioscience Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TAPEX INC
KO:055490
|
0.003x |
|
Total Soft Bank Ltd
KQ:045340
|
0.094x |
|
Garuda Metalindo Tbk PT
JK:BOLT
|
-0.092x |
|
Emmis Communications Corp
PINK:EMMS
|
-0.068x |
|
Shinyoung Waco
KO:005800
|
0.040x |
|
RTRZY
OTCGREY:RTRZY
|
N/A |
|
Bluerock Homes Trust Inc.
NYSE MKT:BHM
|
0.021x |
|
Antisense Therapeutics Limited
PINK:ATHJF
|
-0.287x |
Annual Cash Flow Conversion Efficiency for NexturnBioscience Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of NexturnBioscience Co. Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩136.62 Billion | ₩-1.14 Billion | -0.008x | +41.40% |
| 2023-12-31 | ₩138.01 Billion | ₩-1.97 Billion | -0.014x | -29.82% |
| 2022-12-31 | ₩108.27 Billion | ₩-1.19 Billion | -0.011x | -127.83% |
| 2021-12-31 | ₩92.73 Billion | ₩3.66 Billion | 0.040x | +1520.67% |
| 2020-12-31 | ₩96.77 Billion | ₩235.94 Million | 0.002x | -91.07% |
| 2019-12-31 | ₩100.16 Billion | ₩2.74 Billion | 0.027x | -72.91% |
| 2018-12-31 | ₩95.51 Billion | ₩9.63 Billion | 0.101x | +81.94% |
| 2017-12-31 | ₩91.77 Billion | ₩5.08 Billion | 0.055x | -72.15% |
| 2016-12-31 | ₩89.89 Billion | ₩17.88 Billion | 0.199x | +211.78% |
| 2015-12-31 | ₩30.04 Billion | ₩1.92 Billion | 0.064x | -71.37% |
| 2014-12-31 | ₩29.08 Billion | ₩6.48 Billion | 0.223x | -- |